Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer

Nakamura,Ayako; Hayashi,Kazuhiko; Nakajima,Go; Kamikozuru,Hirotaka; Okuyama,Ryuji; Kuramochi,Hidekazu; Hatori,Takashi; Yamamoto,Masakazu

doi:10.3892/etm.2011.340

Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer

Authors:
- Ayako Nakamura
- Kazuhiko Hayashi
- Go Nakajima
- Hirotaka Kamikozuru
- Ryuji Okuyama
- Hidekazu Kuramochi
- Takashi Hatori
- Masakazu Yamamoto
View Affiliations

Affiliations: Field of Chemotherapy on Digestive Organs, Division of Gastrointestinal Surgery, Graduate School of Medicine, Tokyo Women's Medical University, Tokyo 162-8666, Japan, Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University, Tokyo 162-8666, Japan, Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo 162-8666, Japan
Published online on: August 22, 2011 https://doi.org/10.3892/etm.2011.340
Pages: 1097-1103

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene expression analyses may play useful roles in determining the prognosis of cancer patients and in selecting antitumor drugs. This retrospective study examined potential prognostic factors in patients with pancreatic cancer who received adjuvant chemotherapy after surgery. The study group consisted of 79 patients who had received gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer. Using laser-captured microdissection and real-time RT-PCR assay, we quantitatively evaluated the mRNA levels of 10 genes associated with patient prognosis and sensitivity to chemotherapy using paraffin-embedded specimens of the primary tumors resected before the start of adjuvant chemotherapy. In univariate analyses, a low gene expression level of γ-glutamyl hydrolase (GGH) and a high gene expression level of folylpolyglutamate synthase correlated with a favorable outcome. In a multivariate analysis, a low gene expression level of dihydropyrimidine dehydrogenase (DPD) and GGH significantly correlated with outcome (hazard ratio of the high DPD group to the low DPD group: 5.55; 95% confidence interval (CI) 1.27-24.05; P=0.022; the high GGH group to the low GGH group: 3.77; 95% CI 1.04-13.79, P=0.043). For adjuvant chemotherapy of patients with pancreatic cancer, the mRNA level of DPD and GGH may affect the prognosis of these patients.

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin. 56:106–130. 2006.
2	Oettle H and Neuhaus P: Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs. 67:2293–2310. 2007. View Article : Google Scholar : PubMed/NCBI
3	Neoptolemos JP, Dunn JA, Stocken DD, et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
4	Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
5	Neoptolemos J, Büchler M, Stocken DD, et al: ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 27(suppl s18): abs LBA4505,. 2009.(ASCO Annual Meeting).
6	Andersson R, Aho U, Nilsson BI, et al: Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol. 44:782–786. 2009. View Article : Google Scholar : PubMed/NCBI
7	Giovannetti E, del Tacca M, Mey V, et al: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66:3928–3935. 2006. View Article : Google Scholar
8	Ioka T, Ohkawa S, Yanagimoto H, et al: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol. 29:2011.(ASCO Annual Meeting).
9	Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer. 91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ichikawa W and Sasaki Y: Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol. 13:206–211. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kuramochi H, Hayashi K, Uchida K, et al: High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol. 63:85–89. 2008. View Article : Google Scholar
12	Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res. 6:986–994. 1996. View Article : Google Scholar : PubMed/NCBI
13	Miyake K, Imura S, Yoshizumi T, Ikemoto T, Morine Y and Shimada M: Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol. 12:111–119. 2007. View Article : Google Scholar
14	Mori K, Hasegawa M, Nishida M, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol. 17:33–38. 2000.PubMed/NCBI
15	Ichikawa W: Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer. 9:145–155. 2006. View Article : Google Scholar : PubMed/NCBI
16	Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.
17	Takechi T, Fujioka A, Matsushima E and Fukushima M: Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 38:1271–1277. 2002. View Article : Google Scholar
18	Neoptolemos JP, Stocken DD, Tudur Smith C, et al: Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 100:246–250. 2009. View Article : Google Scholar : PubMed/NCBI
19	Larsson SC, Hakansson N, Giovannucci E and Wolk A: Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst. 98:407–413. 2006. View Article : Google Scholar : PubMed/NCBI
20	Sakamoto E, Tsukioka S, Oie S, et al: Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun. 365:801–807. 2008. View Article : Google Scholar
21	Tsukioka S, Uchida J, Tsujimoto H, et al: Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted mice. Mol Med Reports. 2:393–398. 2009.PubMed/NCBI
22	Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007. View Article : Google Scholar : PubMed/NCBI